男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

中文USEUROPEAFRICAASIA
China-Europe Relations

UK fraud office liaising with China on GSK bribery case

( Agencies ) Updated: 2014-07-24 07:50:01

LONDON - Britain's fraud office is working with authorities in China in a first for such Anglo-Chinese cooperation as it carries out its own investigation into alleged corruption at drugmaker GlaxoSmithKline.

"Certainly, so far as I am aware it is the first time we have had cooperation with the Chinese on an SFO case," David Green, the head of the Serious Fraud Office (SFO), said in an interview with Reuters on Wednesday.

Green, who said he had visited China earlier this year, said the Chinese government had a clear interest in rooting out bribery and corruption although it might have "slightly different perspectives" than the SFO.

The SFO launched a formal criminal investigation into Britain's biggest drugmaker in May, posing a new challenge to the company, which has been accused by Chinese police of funnelling up to 3 billion yuan ($480 million) in bribes to encourage doctors to use its medicines.

The SFO action came less than two weeks after Chinese police announced on May 14 that they had charged the former British boss of GSK's China business and other colleagues with corruption.

The US Department of Justice is also investigating GSK for possible breaches of the Foreign Corrupt Practices Act, which prohibits payments to government officials, including state-employed doctors, to obtain business overseas.

Britain's relatively new Bribery Act also prohibits such overseas bribes.

Since the case in China blew up in July last year, allegations of GSK bribery have surfaced in other countries and GSK is now investigating claims that bribes were also paid to doctors in Poland, Iraq, Jordan and Lebanon.

Green said the SFO was looking into GSK's behaviour in a number of jurisdictions, including Europe and the Middle East. In many cases, the facts behind the allegations have still to be established - and his office has asked for assistance from whistleblowers.

"Suffice to say we have a number of sources of information," Green said.

GSK Chief Executive Andrew Witty has described the allegations in China as "shameful". However, he declined to comment in detail about the case when questioned by reporters after presenting second-quarter results.

"I remain very concerned about allegations concerning our China business. The situation is complicated and difficult and while the investigation is active there is little I can add," Witty said.

UK fraud office liaising with China on GSK bribery case UK fraud office liaising with China on GSK bribery case
 Sex video is new twist in GSK China scandal Police reveals more about GSK China's violations

...
主站蜘蛛池模板: 吉木萨尔县| 年辖:市辖区| 闵行区| 高雄县| 怀集县| 咸阳市| 沧州市| 达拉特旗| 伽师县| 玉屏| 威宁| 潮州市| 安仁县| 乐陵市| 永修县| 筠连县| 泌阳县| 鄂伦春自治旗| 泗阳县| 多伦县| 同心县| 轮台县| 临湘市| 新沂市| 新源县| 克什克腾旗| 庄浪县| 民县| 山阴县| 吴旗县| 鄄城县| 察哈| 宜宾县| 永泰县| 克拉玛依市| 开原市| 黄平县| 淮阳县| 通海县| 涟水县| 神农架林区|